Sarepta’s Exondys 51 Successor On Clinical Hold, But Quick Resolution Expected

 
• By Joseph Haas
  
Risk management concept hand drawn on chalkboard
FDA places Sarepta's SRP-5051 on clinical hold to assess hypomagnesemia risk
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D